Seqanswers Leaderboard Ad

Collapse

Announcement

Collapse
No announcement yet.
X
 
  • Filter
  • Time
  • Show
Clear All
new posts

  • Sfaf 2013

    Day 1 highlights of Sequencing, Finishing and Analysis in the Future Meeting (SFAF 2013)

    • All four platforms are actively trying to increase their read lengths (although we didn’t see significant guidance beyond Ion’s 400 bp reads)
    • Haley mentioned that Illumina’s latest aquisition of Moleculo technology might one day replace current Mate-pair library prep (if prices can be lowered).
    • MiSeq DX was pulled back because Illumina has been able to increase MiSeq output. A clinical instrument will require a locked down platform.
    • Turner said that he expects 30,000 PacBio base pairs in 3 years. Shearing technologies and polymerases would have to be improved for better-read lengths.
    • PGM can produce >2G aligned Q20 bases with even coverage (E. coli) using their 318, 400 bp chip.
    • Fiske said that Illumina spends 25% of revenue on R&D, Life Tech and Thermo spend 5% and 3% respectively.
    • Illumina needs help with better and higher fidelity polymerases. Suggested that Illumina would consider purchasing companies who have breakthrough technologies related to polymerases.

    SFAF day 1 summary
    Last edited by Genohub; 07-29-2013, 02:16 PM. Reason: link update

Latest Articles

Collapse

  • seqadmin
    Understanding Genetic Influence on Infectious Disease
    by seqadmin




    During the COVID-19 pandemic, scientists observed that while some individuals experienced severe illness when infected with SARS-CoV-2, others were barely affected. These disparities left researchers and clinicians wondering what causes the wide variations in response to viral infections and what role genetics plays.

    Jean-Laurent Casanova, M.D., Ph.D., Professor at Rockefeller University, is a leading expert in this crossover between genetics and infectious...
    09-09-2024, 10:59 AM
  • seqadmin
    Addressing Off-Target Effects in CRISPR Technologies
    by seqadmin






    The first FDA-approved CRISPR-based therapy marked the transition of therapeutic gene editing from a dream to reality1. CRISPR technologies have streamlined gene editing, and CRISPR screens have become an important approach for identifying genes involved in disease processes2. This technique introduces targeted mutations across numerous genes, enabling large-scale identification of gene functions, interactions, and pathways3. Identifying the full range...
    08-27-2024, 04:44 AM

ad_right_rmr

Collapse

News

Collapse

Topics Statistics Last Post
Started by seqadmin, Today, 06:25 AM
0 responses
13 views
0 likes
Last Post seqadmin  
Started by seqadmin, Yesterday, 01:02 PM
0 responses
12 views
0 likes
Last Post seqadmin  
Started by seqadmin, 09-18-2024, 06:39 AM
0 responses
14 views
0 likes
Last Post seqadmin  
Started by seqadmin, 09-11-2024, 02:44 PM
0 responses
14 views
0 likes
Last Post seqadmin  
Working...
X